Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables: 2017-2024

Historic Receivables for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $318,000.

  • Aclaris Therapeutics' Receivables fell 72.29% to $194,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.1 million, marking a year-over-year decrease of 35.64%. This contributed to the annual value of $318,000 for FY2024, which is 6.71% up from last year.
  • As of FY2024, Aclaris Therapeutics' Receivables stood at $318,000, which was up 6.71% from $298,000 recorded in FY2023.
  • Aclaris Therapeutics' Receivables' 5-year high stood at $1.1 million during FY2020, with a 5-year trough of $298,000 in FY2023.
  • Moreover, its 3-year median value for Receivables was $318,000 (2024), whereas its average is $366,667.
  • As far as peak fluctuations go, Aclaris Therapeutics' Receivables skyrocketed by 33.33% in 2020, and later plummeted by 39.65% in 2021.
  • Aclaris Therapeutics' Receivables (Yearly) stood at $1.1 million in 2020, then plummeted by 39.65% to $647,000 in 2021, then decreased by 25.19% to $484,000 in 2022, then tumbled by 38.43% to $298,000 in 2023, then climbed by 6.71% to $318,000 in 2024.